Cyclacel Pharmaceuticals Inc (CYCC) 2023 Q4 法說會逐字稿

Good afternoon and welcome to the Fibrocell Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast.

下午好，歡迎參加 Fibrocell Pharmaceuticals 2023 年第四季和全年財報電話會議和網路廣播。

At this time, all participants are in a listen only mode.

此時，所有參與者都處於只聽模式。

After today's call, members of the financial community will have the opportunity to ask questions.

今天的電話會議結束後，金融界成員將有機會提問。

If you would like to ask a question at that time, please press star one on your telephone keypad.

如果您當時想提問，請按電話鍵盤上的星號一。

If at any point your question has been answered, you may remove yourself from the queue by pressing star two and posing your question, we ask that you please pick up your handset to allow optimal sound quality.

如果您的問題在任何時候得到解答，您可以透過按星號二並提出您的問題來將自己從隊列中刪除，我們要求您拿起聽筒以獲得最佳音質。

Lastly, if at any time during the call you should require operator assistance, please press star zero.

最後，如果在通話過程中的任何時間您需要接線員幫助，請按星號零。

Please note, today's call is being recorded.

請注意，今天的通話正在錄音。

I would now like to turn the conference call over to the company.

我現在想把電話會議轉給公司。

Please go ahead.

請繼續。

Good afternoon, everyone, and thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the fourth quarter and financial year ended December 31, 2023.

大家下午好，感謝您參加今天的電話會議，討論 Cyclacel 截至 2023 年 12 月 31 日的第四季度和財年的財務業績和業務亮點。

Before turning the call over to management I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor provision.

在將電話轉交給管理階層之前，我想提醒大家，在本次電話會議中，管理階層所做的前瞻性聲明旨在屬於安全港條款的範圍。

The Private Securities Litigation Reform Act of 1995 and Section 21 E. of the Securities Exchange Act of 1934 as amended as set forth in our press release.

1995 年《私人證券訴訟改革法》和 1934 年《證券交易法》第 21 E. 條經過修訂，如我們的新聞稿所述。

Forward-looking statements involve risks and uncertainties that may affect the Company's business and prospects, including those discussed in our filings with the Securities and Exchange Commission, which include, among other things, our forms 10-Q and 10-K all of our projections and other forward-looking statements represent our judgment as of today, and sequestration does not take any responsibility to update such information with us today, our CEO and Vice President and Chief Executive Officer, Tom McCann, Executive Vice President, Finance and Chief Operating Officer, and Dr. Brian Schwartz, Chief Medical Officer.

前瞻性陳述涉及可能影響公司業務和前景的風險和不確定性，包括我們向美國證券交易委員會提交的文件中討論的風險和不確定性，其中包括我們的10-Q 和10-K 表格中的所有預測和其他前瞻性陳述代表我們截至今天的判斷，封存不承擔任何責任，今天向我們更新這些信息，我們的首席執行官兼副總裁兼首席執行官、財務執行副總裁兼首席運營官 Tom McCann和首席醫療官Brian Schwartz 博士。

Here I will begin with an overview of our business strategy and progress.

在這裡，我將首先概述我們的業務策略和進展。

Diane will provide detail on Cypress U.S. clinical programs, and then Paul will provide financial highlights for the fourth quarter and full year 2023, which we followed by Q & A. session.

Diane 將提供賽普拉斯美國臨床項目的詳細信息，然後 Paul 將提供第四季度和 2023 年全年的財務要點，隨後我們將進行問答環節。

At this time, I'd like to turn the call over to Pierre.

這時，我想把電話轉給皮埃爾。

Thank you, Grace, and thank you, everyone, for joining us today for our fourth quarter and full year 2023 business update.

謝謝 Grace，也謝謝大家今天加入我們，了解我們的 2023 年第四季和全年業務更新。

We are delighted to be joined on today's call by Dr. Brian Schwartz, who has recently joined Cyclacel as Chief Medical Officer, many of you may know, Brian, when he was CMO at Archeo prior to the acquisition by Merck in 2020, at which time he joined our Board of Directors, he has extensive clinical and product development experience, which will be instrumental in guiding our team to deliver key value inflection milestones.

我們很高興邀請 Brian Schwartz 博士參加今天的電話會議，他最近加入 Cyclacel 擔任首席醫療官，你們很多人可能都知道，Brian，在 2020 年被默克收購之前，他在 Archeo 擔任首席營銷官，當時在加入我們的董事會時，他擁有豐富的臨床和產品開發經驗，這將有助於指導我們的團隊實現關鍵的價值轉折點里程碑。

We are pleased to report on the progress of fadraciclib, our CDK2 and nine inhibitor or fadra.

我們很高興地報告 fadraciclib、我們的 CDK2 和九種抑制劑或 fadra 的進展。

For short, having recently discovered a potential precision medicine approach for fadra, we have determined the recommended Phase two dose or RP2D and are ready to start the Phase two proof of concept part of our oh six five dash one oh one study.

簡而言之，最近發現了一種潛在的fadra 精準醫學方法，我們已經確定了建議的第二階段劑量或RP2D，並準備開始我們的oh 6 5 dash 1 oh one 研究的第二階段概念驗證部分。

Taken together, our clinical and preclinical data suggest the hypothesis, but patients with one or more chromosomal abnormalities, including CDKN. two ACDKN. two b. and or Enpath, including deep deletions or loss of function, may be sensitive to fadra in this part we will evaluate patient cohorts selected for their mutational profile and or Phase one activity in various solid tumors and lymphoma.

綜上所述，我們的臨床和臨床前數據表明了這一假設，但患有一種或多種染色體異常（包括 CDKN）的患者。兩個ACDKN。二灣和/或 Enpath，包括深度缺失或功能喪失，可能對 fadra 敏感。在這一部分，我們將評估根據突變譜和/或各種實體瘤和淋巴瘤的一期活性選擇的患者群體。

We will initially focus on two patient cohorts with CDKN. two A. and or CDKN. to be abnormalities and T cell lymphoma from both of which we saw Phase one signals of activity, including responses.

我們首先將重點放在兩個 CDKN 患者群組。兩個A.和/或CDKN。異常和 T 細胞淋巴瘤，我們從中看到了第一階段的活動訊號，包括反應。

We believe that there is great unmet medical need and industry interest in the cancer patient populations identified by these formalities, which are closely located on chromosome nine and are often called deleted CDKN. two A. gene deletions of Kerr in several solid tumors, including bladder, breast and the Nutrio esophageal glioma, head-and-neck hepatobiliary lung, including squamous melanoma, ovarian, pancreatic, and also in certain T-cell lymphomas.

我們相信，透過這些手續確定的癌症患者群體存在巨大的未滿足的醫療需求和行業興趣，這些患者群體緊密位於九號染色體上，通常被稱為刪除的 CDKN。兩種A.克爾基因缺失存在於多種實體瘤中，包括膀胱、乳房和Nutrio食道神經膠質瘤、頭頸肝膽肺，包括鱗狀黑色素瘤、卵巢、胰腺，以及某些T細胞淋巴瘤。

CDKN. two BD lesions occur in several solid tumors, including bladder, breast, cholangiocarcinoma and the VTO and sofa geo glioma, head and neck hepatobiliary land, including squamous and mesothelioma, melanoma, pancreatic and others.

CDKN。兩種BD病變發生於多種實體腫瘤，包括膀胱癌、乳癌、膽管癌以及VTO和沙發膠質瘤，頭頸肝膽地包括鱗狀細胞瘤和間皮瘤、黑色素瘤、胰臟癌等。

As mentioned in our press release, we expect two key data readouts for five drugs this year, final data from the dose escalation part of the oh six, I have dash one oh one study at a major medical conference and later on initial clinical activity for the Phase two proof of concept part also at the upcoming ACR 2024 meeting, independent investigators will present the clinical proof of concept data for fadra in various tumor types.

正如我們在新聞稿中提到的，我們預計今年將有五種藥物的兩個關鍵數據讀數，來自「哦六」劑量遞增部分的最終數據，我在一次重要的醫學會議上進行了一對一研究，以及隨後的初步臨床活動第二階段概念驗證部分也在即將召開的 ACR 2024 會議上，獨立研究人員將展示 fadra 在各種腫瘤類型中的臨床概念驗證數據。

I will now turn the call over to Brian to review our progress in the fadra and longer studies and discuss some of our clinical results.

我現在將把電話轉給布萊恩，回顧我們在 fadra 和長期研究方面的進展，並討論我們的一些臨床結果。

Brian.

布萊恩.

Thank you, Stereo.

謝謝你，立體聲。

We have dosed 47 patients in the dose escalation part of the fadra oh six, five one oh one study, of which 33 are evaluable for efficacy.

我們在 fadra oh 6, 5 1 oh 1 研究的劑量遞增部分對 47 名患者進行了給藥，其中 33 名患者可進行療效評估。

We have completed dose escalation and based on preclinical and clinical data have determined that dose level five or 100 milligrams BID dose, five days per week in a four week cycle will be our recommended Phase two dose or RPDDRP. two D no dose-limiting toxicities have been observed at this dose level.

我們已經完成了劑量遞增，並根據臨床前和臨床數據確定了劑量水平 5 或 100 毫克 BID 劑量，每週 5 天，在 4 週的周期中將是我們推薦的第二階段劑量或 RPDDRP。 2 D 在此劑量水準下未觀察到劑量限制性毒性。

We have also observed CDKN. two A. or B alterations, including loss of function in multiple pretreated Phase one patients with various cancers, including gynecological, hepatobiliary, lung and pancreatic, who have benefited from Pharmacyclics monotherapy.

我們也觀察到了CDKN。兩個 A. 或 B 改變，包括患有多種癌症（包括婦科癌症、肝膽癌、肺癌和胰腺癌）的多個經過一期治療的患者的功能喪失，這些癌症已從 Pharmacyclos 單一療法中受益。

These patient groups are associated with a high unmet medical need and often have poor clinical outcomes.

這些患者群體的醫療需求未被滿足，臨床結果往往較差。

An illustration of this is we were excited to see shrinkage of 22% in the sum of all target lesions after one cycle of oral fadraciclib in a squamous non-small cell lung cancer patient with CDKN. 2b deletion refractory to standard of care chemotherapy and immunotherapy of the retrospectively analyzing the subset of previously treated Phase one patients who experienced clinical benefit with fadra, we found an additional five patients with CDKN. two A. or CDKN. to be alterations.

一個例證是，我們很高興地看到一位患有 CDKN 的鱗狀非小細胞肺癌患者在口服 fadraciclib 一個週期後，所有目標病變的總和縮小了 22%。 2b 刪除對護理標準化療和免疫治療難治性回顧性分析了既往接受過 fadra 臨床獲益的一期患者子集，我們發現了另外 5 名 CDKN 患者。兩個 A. 或 CDKN。予以變更。

These included an endometrial cancer patient who achieved the CR and over three years on treatment in a previous study with IV fadra as monotherapy and was found to have CDKN. two ACDKN. two b. and NTAP. loss.

其中包括一名子宮內膜癌患者，該患者在先前的靜脈注射 fadra 作為單一療法的研究中獲得 CR 並接受了三年多的治療，並被發現患有 CDKN。兩個ACDKN。二灣和NTAP。損失。

We are also encouraged by Phase one anticancer activity observed in our T cell lymphoma patients, including PRs in two out of three patients per cohort in Part two of the slide 1 oh one will evaluate patients with T-cell lymphoma.

我們也對在T 細胞淋巴瘤患者中觀察到的一期抗癌活性感到鼓舞，包括幻燈片1 的第二部分中每組三分之二的患者獲得PR，其中第一部分將評估T 細胞淋巴瘤患者。

Although the Phase one hypothesis generating data are limited and cannot be generalized.

儘管第一階段假設產生的數據有限且不能概括。

We believe patients with these cancer types should be evaluated in the Phase two proof-of-concept part of the study.

我們認為患有這些癌症類型的患者應該在研究的第二階段概念驗證部分進行評估。

Initially, we expect to enroll 10 to 12 patients in each of the two cohorts with CDKN. two A. or B alterations and T-cell lymphoma.

最初，我們預計在兩個 CDKN 隊列中各招募 10 至 12 名患者。兩個 A. 或 B 改變和 T 細胞淋巴瘤。

We estimate that approximately eight sites will take part in the Phase two and have completed several site initiation visits so we can quickly start enrollment and deliver results by the second half of 2024.

我們估計大約有 8 個站點將參與第二階段，並已完成多次站點啟動訪問，因此我們可以快速開始註冊並在 2024 年下半年之前交付結果。

Let me now make a few remarks on our second program logo, certain programs in the one 4101 dose escalation study of Glogów.

現在讓我對我們的第二個項目標誌、Glogów 一項 4101 劑量遞增研究中的某些項目發表一些評論。

We have enrolled 15 patients with good tolerability so far, although we observed early evidence of anticancer activity in multiple patients.

到目前為止，我們已經招募了 15 名耐受性良好的患者，儘管我們在多名患者中觀察到了抗癌活性的早期證據。

Preclinical and clinical data suggest that the optimum dosing may be achieved with an alternative salt formulation of logo, which has been under development.

臨床前和臨床數據表明，可以透過正在開發的替代鹽製劑來實現最佳劑量。

Additionally, independent groups have shown that certain Arrid 1A or smart CA mutated cancers may benefit from treatment with Plug Arrid and other mutations are found in several cancers, including bladder, endometriosis, esophageal hepatobiliary and colorectal.

此外，獨立研究小組表明，某些Arrid 1A 或smart CA 突變癌症可能受益於Plug Arrid 的治療，並且在多種癌症中發現了其他突變，包括膀胱癌、子宮內膜異位症、食道肝膽癌和大腸直腸癌。

For these reasons, we have chosen to pause one 4101 study with a current formulation and resume dose escalation once the new formulation becomes available following assessment of bioavailability in patients.

基於這些原因，我們選擇暫停一項使用目前製劑的 4101 研究，並在評估患者的生物利用度後一旦新製劑可用，就恢復劑量遞增。

We will now be taking into account potential selection biomarkers for patients enrolling in one 4101 study.

我們現在將考慮參加 4101 研究的患者的潛在選擇生物標記。

I will now turn the call over to Paul to review the fourth quarter and full year results.

現在我將把電話轉給保羅，讓他回顧第四季和全年的表現。

Thank you, Brian.

謝謝你，布萊恩。

As of December 31, 2023, pro forma cash and cash equivalents totaled $6.3 million, including $2.9 million of United Kingdom research and development tax credits received after the end of the year.

截至2023年12月31日，預計現金及現金等價物總額為630萬美元，其中包括年底後收到的290萬美元的英國研發稅收抵免。

Cash and cash equivalents as of December 31, 2023 totaled $3.4 million compared to $18.4 million as of December 31, 2022.

截至 2023 年 12 月 31 日，現金及現金等價物總額為 340 萬美元，而截至 2022 年 12 月 31 日為 1,840 萬美元。

Net cash used in operating activities was $16.1 million for the 12 months ended December 31, 2023, compared to $20.8 million for the same period of 2022.

截至 2023 年 12 月 31 日的 12 個月，經營活動使用的現金淨額為 1,610 萬美元，而 2022 年同期為 2,080 萬美元。

The Company estimates that its available cash, including the United Kingdom research and development tax credit received of $2.9 million will fund currently planned programs into the second quarter of 2024.

該公司估計其可用現金，包括收到的 290 萬美元的英國研發稅收抵免，將為當前計劃的項目提供資金到 2024 年第二季。

Research and development or R&D expenses were $3.5 million and $19.2 million for the three months and year ended December 31st, 2023, as compared to $6.7 million and $20.3 million for the same period in 2022.

截至 2023 年 12 月 31 日止三個月及一年，研發費用分別為 350 萬美元及 1,920 萬美元，而 2022 年同期為 670 萬美元及 2,030 萬美元。

R&D expenses relating to fadra were $2.7 million and $13.4 million for the three months and year ended December 31, 2023, as compared to $5.3 million and $14 million for the same period in 2022 period due to a decrease in clinical trial costs, offset by an increase in manufacturing and other nonclinical expenditures.

截至2023 年12 月31 日止三個月和一年，與fadra 相關的研發費用分別為270 萬美元和1,340 萬美元，而2022 年同期為530 萬美元和1,400 萬美元，原因是臨床試驗成本減少，但被製造和其他非臨床支出的增加。

R&D expenses related to flow go were $0.7 million and $5 million for the three months and year ended December 31, 2023 as compared to $1.3 million and $5.5 million for the same period in 2022 due to decrease in manufacturing and other nonclinical expenditures.

截至2023 年12 月31 日止三個月和一年，與流程相關的研發費用分別為70 萬美元和500 萬美元，而2022 年同期為130 萬美元和550 萬美元，原因是製造和其他非臨床支出減少。

General and administrative expenses for the three months and year ended December 31, 2023 were $1.9 million and $6.7 million compared to $2.1 million and $7.4 million for the same period of the previous year due to a decrease in professional fees.

截至 2023 年 12 月 31 日止三個月及一年的一般及行政費用分別為 190 萬美元及 670 萬美元，而上年同期為 210 萬美元及 740 萬美元，原因是專業費用減少。

Total other income net for the three months and year ended December 31, 2023, were an expense of $0.3 million and an expense of $0.1 million compared to an expense of $0.2 million and income of $1.7 million for the same period of the previous year.

截至 2023 年 12 月 31 日的三個月和一年的其他收入淨額總額為支出 30 萬美元和支出 10 萬美元，而上年同期支出為 20 萬美元，收入為 170 萬美元。

The decrease of $1.8 million for the year ended December 31, 2023, is primarily related to royalty income received in the previous year.

截至 2023 年 12 月 31 日止年度減少 180 萬美元，主要與上一年收到的特許權使用費收入有關。

United Kingdom research and development tax credits for the three months and year ended December 31, 2023, $0.4 million and $3 million compared to $1.6 million and $4.7 million for the same period of the previous year and are directly correlated to qualifying research and development expenditure.

截至2023年12月31日的三個月和一年，英國的研發稅收抵免分別為40萬美元和300萬美元，而上年同期為160萬美元和470萬美元，並且與合格的研發支出直接相關。

Net loss for the three months and year ended December 31, 2023, was $5.3 million and $22.6 million, including stock-based compensation expense of $0.3 million and $1.5 million, respectively, compared to $7.4 million and $21.2 million, including a given stock-based compensation expense of $0.3 million and $1.5 million, respectively, for the same period in 2022.

截至2023 年12 月31 日的三個月和一年的淨虧損分別為530 萬美元和2,260 萬美元，其中包括基於股票的補償費用分別為30 萬美元和150 萬美元，而淨虧損分別為740萬美元和2,120 萬美元，包括基於股票的補償費用2022 年同期的補償費用分別為 30 萬美元和 150 萬美元。

Operator, we are now ready to take questions.

接線員，我們現在準備好回答問題。

Thank you, sir.

謝謝你，先生。

At this time, if you'd like to ask a question, please press the star and one on your telephone keypad.

此時，如果您想提問，請按電話鍵盤上的星號和一。

You may remove yourself from the queue at any time by pressing star two.

您可以隨時按二號星將自己從佇列中刪除。

Once again, that is star one to ask a question.

再說一次，這是提問的明星。

We will pause for a moment to allow questions to queue.

我們將暫停片刻，讓問題排隊。

Our first question comes from RVU Demir with Ladenburg Thalmann.

我們的第一個問題來自 RVU Demir 和 Ladenburg Thalmann。

Good afternoon.

午安.

Thanks for taking my question and Brian, but come back Great to see you back on the operational piece.

感謝您提出我的問題和布萊恩，但回來很高興看到您回到操作部分。

I have two questions.

我有兩個問題。

First one is on the fadra program.

第一個是fadra 計劃。

You have two major data readouts you mentioned for the Phase one portion of the data readouts.

對於數據讀數的第一階段部分，您有兩個主要的數據讀數。

Are you going to disclose any of the PD biomarker data, including CDKN. two ABNV. or others?

您是否打算揭露任何 PD 生物標記數據，包括 CDKN。兩個 ABNV。或其他？

That's my first question.

這是我的第一個問題。

Okay.

好的。

Thank you very much for your question, not only us, yes, we intend to disclose some of the previous data in the middle of completing that as being a part of the remarks and the press release, we have six stations that have the specific genotype surveying comparative for the visit with the best patients.

非常感謝您的提問，不僅僅是我們，是的，我們打算在完成過程中披露一些先前的數據，作為評論和新聞稿的一部分，我們有六個具有特定基因型的站調查比較最佳患者的就診情況。

As far as response for this, clearly hypothesis-generating data set and we'll look to share more with our investors.

至於對此的回應，顯然是假設生成的數據集，我們將尋求與投資者分享更多資訊。

Welcome to the conference call.

歡迎參加電話會議。

And then my second question is on the Pogo formulation.

我的第二個問題是關於 Pogo 的發展。

As the clinical studies are currently not ongoing, when do you think the formulation efforts will be completed?

由於目前臨床研究尚未進行，您認為製劑何時能完成？

And when do you think you will resume the clinical as for?

您認為什麼時候可以恢復臨床？

And also, when are we going to PETER data clinical data from this program.

另外，我們什麼時候才能取得該計畫的 PETER 臨床數據。

We'll will ask Paul, who's in charge of our manufacturing effort.

我們會詢問負責我們製造工作的保羅。

To comment on the first question, I will discuss second one to.

針對第一個問題，我將討論第二個問題。

Yes, we in the end, the formulation the all new formulation of positive is ongoing.

是的，我們最終，所有新的積極的發展正在進行中。

We've been doing from a short while, so we'd anticipate about six months to complete that process started.

我們已經這樣做了很短一段時間，因此我們預計大約需要六個月的時間來完成該過程。

As far as the clinical data with the second part of your question, I don't know, 16 patient seen than a comparator in 2014 tumor shrinkage then on stable disease and levels of patients.

至於你問題第二部分的臨床數據，我不知道，2014 年有 16 名患者的腫瘤縮小，然後疾病和患者水準穩定。

We need to make sure we can get to targeting it one volt because we have that backup utilization on the alternative salt with gear was much higher exposures.

我們需要確保我們能夠將其目標定為一伏，因為我們對帶有齒輪的替代鹽的備用利用率要高得多。

We obviously need to go with that that's the reason to pause the program of improving backdrop.

顯然我們需要遵循這一點，這就是暫停改善背景計畫的原因。

Netiq's.

內提克的。

Thank you.

謝謝。

Our next question comes from Kemp Dolliver, Brookline Capital Markets.

我們的下一個問題來自布魯克林資本市場公司的 Kemp Dolliver。

Thank you.

謝謝。

Cheryl, the press release and your transcript refers to the cash runway going into second quarter, which is, as you know, is a short period of time away.

謝麗爾，新聞稿和你的文字記錄提到了進入第二季的現金跑道，正如你所知，距離第二季還有很短的一段時間。

So two questions related to that.

有兩個與此相關的問題。

How far into the second quarter.

距離第二季還有多久。

Can you continue operating?

可以繼續經營嗎？

And then which has a lot of milestones, what can you achieve before between now and then?

然後有很多里程碑，從現在到那時你可以實現什麼？

Patrick, we can go into April of 2024.

派崔克，我們可以進入 2024 年 4 月。

And with that one can imagine that this processes both in any way as far as raising additional funds as well as considering other options for the strategic plan.

由此可以想像，無論是籌集額外資金還是考慮戰略計劃的其他選擇，這個過程都會以任何方式進行。

Well, as far as milestones are concerned, and we expect to begin our Phase two program that have extraordinary environment that Coca-Cola as it until the Collins Phase one ongoing Phase two.

好吧，就里程碑而言，我們預計將開始我們的第二階段計劃，該計劃擁有與可口可樂一樣的非凡環境，直到柯林斯第一階段正在進行第二階段。

Listen, I appreciate the clarity to the enrolling Phase two.

聽著，我很欣賞第二階段招生的明確性。

And it's a question of when we see the abstracts from major medical meeting in the middle of the year was historically come out of the month far.

問題是，我們什麼時候才能看到年中大型醫學會議的摘要在歷史上遠遠超出了本月。

So expect to see those are on the same timeframe just to contain the Phase one data for Phase one data, including some detail on the pharmacodynamic profiles of patients, but not all of them because the cutoff was in winter, we expect cash flow that's in the public domain within this time frame.

因此，期望看到這些數據在同一時間範圍內，僅包含第一階段數據的第一階段數據，包括患者藥效學概況的一些詳細信息，但不是全部，因為截止日期是在冬季，我們預計現金流量為在此時間範圍內屬於公共領域。

Great.

偉大的。

Thank you.

謝謝。

Thank you, Brain.

謝謝你，布萊恩。

We have no further questions at this time.

目前我們沒有進一步的問題。

I would now like to turn the call back over to the company for any additional our closing remark.

我現在想將電話轉回公司，以徵求我們的任何補充結束語。

Thanks, operator, and thanks to all of you for joining southwest of Fourth Quarter and Full Year 2023 earnings call.

感謝營運商，感謝大家參加西南地區 2023 年第四季和全年財報電話會議。

Pharmacyclics has achieved a key milestone in ready to start Phase two proof of concept stage with important catalysts anticipated volume target for a strong competitive profile therapeutic class.

Pharmacyclos 在準備啟動第二階段概念驗證階段取得了一個重要的里程碑，並實現了具有強大競爭力的治療類別的預期銷售目標。

As a reminder, our upcoming key milestones are first patient dosed with oral fadraciclib in Phase two proof of concept part of oh six, higher ash one oh one study in patients with advanced solid tumors and lymphoma.

提醒一下，我們即將到來的關鍵里程碑是，在針對晚期實體瘤和淋巴瘤患者的 oh 6、高灰分一對一研究的第二階段概念驗證部分中，第一位患者接受口服 fadraciclib 給藥。

We report final data from dose escalation stage from us.

我們報告劑量遞增階段的最終數據。

If you have that one-to-one, again, more optimistically in patients with advanced solid tumors and lymphoma report interim data from initial cohorts in Phase two open label proof-of-concept part of the success of Cashland one study with oral fadra cited in patients with advanced solid tumors and lymphoma and the independent investigators to report clinical proof-of-concept data for Pharmacyclics at the American Association for Cancer Research or AACR Annual Meeting 2024.

如果您對晚期實體瘤和淋巴瘤患者進行一對一的治療，則更樂觀地報告第二階段開放標籤概念驗證的初始隊列的中期數據，這是 Cashland 一項口服 fadra 引用的研究成功的一部分晚期實體瘤和淋巴瘤患者以及獨立研究人員在美國癌症研究協會或AACR 2024 年年會上報告Pharmacyclos 的臨床概念驗證數據。

We look forward to providing further updates and also meet some of you out in conferences conference at this time, you may end the call.

我們期待提供進一步的更新，並在會議中與你們中的一些人見面，此時您可以結束通話。

Thank you, sir, this does conclude today's program.

謝謝先生，今天的節目到此結束。

Thank you for your participation.

感謝您的參與。

You may disconnect at any time.

您可以隨時斷開連線。